Boston Scientific (NYSE:BSX) shares declined roughly 9% after the company published top-line results from the CHAMPION-AF trial evaluating the Watchman FLX Left Atrial Appendage Closure device as a first-line alternative to non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
The study achieved all its primary and secondary safety and efficacy endpoints, but investors reacted to a small increase in ischemic stroke incidence in the device arm compared with NOAC therapy. Specifically, the trial reported an event rate for cardiovascular death, stroke, and systemic embolism of 5.7% for Watchman versus 4.8% for NOACs. In contrast, the Watchman device demonstrated a lower bleeding rate of 10.9% compared with 19% for NOACs.
Market commentary highlighted the nuance in the dataset. Wells Fargo analyst Larry Biegelsen, while maintaining an overweight rating, characterized the outcome as "were good, not great." He added, "Although the CHAMPION-AF trial met its endpoints, we think the data is unlikely to accelerate Watchman growth given a slightly higher ischemic stroke rate." Biegelsen indicated he does not expect the results to meaningfully speed adoption in the left atrial appendage closure market.
Leerink Partners framed the findings as "not the home-run scenario" that bullish investors had hoped for. Analyst Mike Kratky, who continues to carry an outperform rating, suggested opposition investors will scrutinize details in the data, including the slightly higher ischemic stroke rates observed with the device compared to NOAC therapy.
On the analyst rating front, Raymond James analyst Jayson Bedford reduced his view on Boston Scientific from Strong Buy to Outperform and lowered his price target to $88 from $97. By contrast, Truist Securities kept a Buy rating with a $92 target, and Stifel maintained its Buy rating with a $90 target.
Investors and market participants are weighing the trade-offs illustrated by the CHAMPION-AF readout: a modestly higher ischemic stroke incidence alongside a materially lower bleeding rate. The combination of those outcomes appears to have tempered enthusiasm among some analysts and shareholders, producing notable downward pressure on the stock price.
Context and next steps
The data release has prompted a mix of firm-level reactions from sell-side analysts, with some lowering expectations and others preserving bullish ratings. How the market and clinicians incorporate the marginal differences in ischemic stroke rates versus the bleeding benefit will shape near-term sentiment and any potential impact on Watchman adoption rates.